DNA Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global DNA Sequencing Market is projected to expand from USD 15.56 Billion in 2025 to USD 47.14 Billion by 2031, registering a CAGR of 20.29%. DNA sequencing is characterized as the exact identification of the nucleotide base order within a DNA molecule, achieved through advanced instrumentation, consumables, and bioinformatics services that decode genetic data. The market's upward trajectory is chiefly driven by the continuous decline in sequencing costs and the rising clinical requirement for personalized medicine, specifically within oncology and rare disease diagnostics. These core drivers differ from temporary technological trends and are bolstered by the immense scale of genomic data production; for instance, the Global Alliance for Genomics and Health reported that in 2024, their partner network managed over 3,000,000 genomes, demonstrating the significant volume of genetic material currently employed in research and clinical settings.

However, a major obstacle limiting wider market growth is the increasingly intricate regulatory landscape, particularly regarding the supervision of Laboratory Developed Tests (LDTs). The escalating uncertainty regarding compliance and approval processes for these diagnostic assays forms a commercialization bottleneck, which could potentially delay the swift integration of sequencing technologies into clinical environments despite rising demand.

Market Drivers

Swift technological progress in Next-Generation Sequencing Platforms is transforming the market structure by reducing entry barriers and facilitating high-throughput analysis. This momentum is defined by the arrival of new benchtop sequencers and chemistry upgrades that lower the cost per gigabase, effectively decentralizing genomic capabilities beyond large-scale genome centers.

The significant investment in these disruptive technologies highlights their essential role in market expansion; for example, Element Biosciences announced in its 'Series D Funding Announcement' in July 2024 that it raised $277 million to hasten the commercial launch of its AVITI benchtop sequencer. Such developments create a competitive landscape that forces incumbent companies to innovate, benefiting users through enhanced data quality and lower costs. To demonstrate the scale of this high-tech sector, Illumina reported third-quarter core revenue of $1.1 billion in 2024, indicating continued global dependence on sequencing infrastructure.

The hastened adoption of Precision Medicine and Pharmacogenomics acts as the second major catalyst for market growth, especially within oncology. As sequencing becomes embedded in clinical routines, there is a surge in demand for liquid biopsy and minimal residual disease (MRD) monitoring, enabling non-invasive tumor profiling and tailored treatment strategies. This shift is substantiated by the rapidly increasing volume of diagnostic tests for cancer patients. For instance, Natera reported in its 'Third Quarter 2024 Financial Results' in November 2024 that it processed roughly 137,100 oncology tests, a 54% rise over the same period the previous year. This swift adoption illustrates how clinicians increasingly depend on genomic data for therapeutic decisions, transforming sequencing from a research instrument into a critical standard of care for managing complex conditions.

Market Challenges

The central obstacle hindering the Global DNA Sequencing Market is the progressively complex regulatory framework governing Laboratory Developed Tests (LDTs). This intensified scrutiny generates uncertainty, compelling clinical laboratories to redirect essential resources from innovation toward compliance efforts. As regulators aim to reclassify these assays as medical devices, the projected costs and administrative workloads linked to premarket reviews and quality system standards become exclusionary. Consequently, laboratories are less inclined to invest in novel sequencing technologies or broaden their testing menus, which directly suppresses the commercial uptake of advanced genomic applications.

This regulatory bottleneck curbs market growth by forcing service providers to reduce their offerings, specifically for niche diagnostics. The financial burden of adhering to strict approval protocols often exceeds the revenue potential of low-volume tests employed in rare disease detection. According to a 2024 survey by the Association for Diagnostics and Laboratory Medicine, over 50% of clinical laboratories intended to stop offering certain laboratory-developed tests due to the operational and financial strains resulting from the new FDA oversight rule. This decrease in available diagnostic options restricts patient access to sequencing-based treatments, thereby lowering the total demand for sequencing instruments and consumables.

Market Trends

The rise of Third-Generation Long-Read Sequencing Technologies is transforming the market by addressing complex genomic regions that short-read platforms struggle to analyze. These systems read native DNA molecules in real-time, allowing for the accurate identification of structural variants and epigenetic modifications without the bias caused by amplification. This ability is fueling growing adoption in clinical research and applied markets, where complete genomic visibility is essential for studying large-scale genetic variation. For example, Oxford Nanopore Technologies reported in its 'Annual results for the year ended 31 December 2024' released in March 2025 that revenue reached £183.2 million, an 11.1% increase on a constant currency basis, attributed to the wider use of its platform.

Concurrently, the integration of Artificial Intelligence and Machine Learning for Genomic Analysis is proving indispensable for interpreting the massive amounts of data produced by modern sequencers. As the primary bottleneck shifts from data generation to analysis, AI-powered models are being utilized to speed up variant calling and functional prediction. These algorithms enable researchers to detect disease-causing mutations more rapidly, greatly enhancing the value of genomic data for precision medicine. Highlighting this trend, 10x Genomics announced in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 the initiation of the Billion Cells Project, aiming to create a one billion cell dataset specifically to drive rapid advancements in AI model development.

Key Players Profiled in the DNA Sequencing Market

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• QIAGEN N.V.
• Merck KGaA
• Macrogen, Inc.
• PerkinElmer, Inc.
• Eurofins Scientific Limited

Report Scope

In this report, the Global DNA Sequencing Market has been segmented into the following categories:

DNA Sequencing Market, by Product Type:

• Instruments
• Consumables
• Services

DNA Sequencing Market, by Technology:

• Sanger Sequencing
• Next-Generation Sequencing (NGS)
• Third-Generation Sequencing
• Others

DNA Sequencing Market, by Application:

• Diagnostics
• Research
• Personalized Medicine
• Forensic Testing
• Others

DNA Sequencing Market, by End User:

• Hospitals and Healthcare Organizations
• Academics and Research Institutions
• Pharmaceutical and Biotechnology Companies
• Others

DNA Sequencing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Sequencing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.